Internal Medicine, Pulmonary Disease · Los Angeles, CA
NPI
1982221958
Since 2020
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1520 San Pablo St Ste 1000
Los Angeles, CA, 90033
Phone (323) 442-5100
Groups this clinician bills Medicare through
Medicare paid, 2024
$59K
782 services
Medicare patients, 2024
284
Average age 72
Drug cost, 2024
$6.3M
2,018 prescriptions
Company payments, 2025
$256K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Toby Maher was code 99214 (office e&m - established), 511 times for 242 patients. In total Toby Maher billed 782 services in 8 codes, and Medicare paid $59K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-11-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 511 | 242 | $74.46 | $38K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 67 | 48 | $13.79 | $924 |
| 99214 Office E&M - Established | Office | 48 | 35 | $107.04 | $5,138 |
| 99215 Office E&M - Established | Facility | 38 | 25 | $110.70 | $4,207 |
| 99204 Office E&M - New | Facility | 33 | 33 | $92.80 | $3,062 |
| 99205 Office E&M - New | Facility | 28 | 28 | $147.60 | $4,133 |
| 99213 Office E&M - Established | Facility | 28 | 26 | $51.01 | $1,428 |
By year: 2022 $34K for 429 services; 2023 $53K for 618 services; 2024 $59K for 782 services.
Medicare prescription drug claims, 2024
In 2024, the drug Toby Maher prescribed most often to Medicare patients was Ofev (Nintedanib Esylate), with 425 prescriptions and refills. In total Toby Maher wrote 2,018 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ofev Nintedanib Esylate | 425 | 429 | 60 | $5.3M |
| Prednisone Generic | 353 | 404 | 120 | $1,799 |
| Azithromycin Generic | 118 | 159 | 66 | $859 |
| Pirfenidone Generic | 113 | 113 | 19 | $188K |
| Mycophenolate Mofetil Generic | 106 | 167 | 27 | $16K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 88 | 97 | 28 | $2,026 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 54 | 58 | 19 | $5,583 |
| Dupixent Pen Dupilumab | 48 | 48 | Under 11 | $174K |
| Levofloxacin Generic | 45 | 45 | 26 | $213 |
| Doxycycline Hyclate Generic | 41 | 41 | 13 | $259 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 39 | 49 | Under 11 | $30K |
| Esbriet Pirfenidone | 31 | 31 | Under 11 | $308K |
| Actemra Actpen Tocilizumab | 25 | 27 | Under 11 | $80K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 25 | 29 | Under 11 | $2,751 |
| Breo Ellipta Fluticasone/Vilanterol | 25 | 34 | Under 11 | $13K |
Brand drugs: 851 claims; generic drugs: 1,167 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Toby Maher $256K ($247K in general payments such as food, travel and fees and $9,555 for research) from 12 companies. The largest payer was Daiichi Sankyo Inc. with $102K.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 3 | $102K |
| Boehringer Ingelheim International GmbH | 43 | $87K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 18 | $26K |
| United Therapeutics Corporation UTHR | 18 | $23K |
| Abbvie Inc. ABBV | 4 | $7,175 |
| GlaxoSmithKline, LLC. GSK | 7 | $3,540 |
| Merck Sharp & Dohme LLC MRK | 3 | $2,880 |
| Chiesi USA, Inc. | 6 | $2,685 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $806 |
| Syndax Pharmaceuticals, Inc. SNDX | 1 | $750 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.